Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. The company's product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. As of June 8, 2023, Satsuma Pharmaceuticals, Inc. operates as a subsidiary of Shin Nippon Biomedical Laboratories, Ltd.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2023-05-11 |
2023-03 |
-0.26 |
N/A |
N/A |
N/A |
2023-03-28 |
2022-12 |
-0.38 |
N/A |
N/A |
N/A |
2022-11-03 |
2022-09 |
-0.57 |
N/A |
N/A |
N/A |
2022-08-09 |
2022-06 |
-0.48 |
N/A |
N/A |
N/A |
2022-05-10 |
2022-03 |
-0.48 |
N/A |
N/A |
N/A |
2022-03-15 |
2021-12 |
-0.47 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-04-18 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2023-03-30 |
Mizuho |
Upgrade |
|
Neutral |
2023-03-30 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-11-15 |
Mizuho |
Downgrade |
Buy |
Neutral |
2022-11-15 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-11-15 |
SVB Leerink |
Downgrade |
Outperform |
Market Perform |
Date |
Name |
Relation |
Quantity |
Description |
2020-08-31 |
ALBRECHT DETLEF |
Officer |
20.21K |
Sale |
2022-11-13 |
COMMODORE CAPITAL LP |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2019-09-16 |
HADLEY HARBOR MASTER INVESTORS CAYMAN II, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
1.11M |
Conversion of Exercise of derivative security |
2022-11-20 |
LEONARD BRADEN MICHAEL |
Beneficial Owner of more than 10% of a Class of Security |
6.59M |
Purchase |
2020-08-31 |
O'NEIL THOMAS PAUL |
Chief Financial Officer |
0.00 |
Sale |
2021-02-25 |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-03-30 |
Bml Capital Management, LLC |
6.44M |
7.08M |
19.43% |
2023-03-30 |
RA Capital Management, L.P. |
5.91M |
6.51M |
17.84% |
2023-03-30 |
NEA Management Company, LLC |
2.29M |
2.52M |
6.92% |
2023-03-30 |
Vanguard Group, Inc. (The) |
920.52K |
1.01M |
2.78% |
2023-03-30 |
Geode Capital Management, LLC |
414.34K |
455.78K |
1.25% |
2023-03-30 |
Lion Point Capital, LP |
319.74K |
351.72K |
0.96% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-12-30 |
Vanguard Total Stock Market Index Fund |
522.52K |
574.77K |
1.58% |
2022-12-30 |
Vanguard Extended Market Index Fund |
337.14K |
370.85K |
1.02% |
2023-03-30 |
Fidelity NASDAQ Composite Index ETF |
217.69K |
239.46K |
0.66% |
2023-02-27 |
Fidelity Extended Market Index Fund |
102.80K |
113.08K |
0.31% |
2023-01-30 |
DFA U.S. Small Cap Series |
88.16K |
96.98K |
0.27% |
2022-12-30 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
65.00K |
71.50K |
0.20% |
Dividend |
Date |
0.2 |
2014-03-28 |
0.2 |
2014-02-11 |
0.2 |
2013-11-01 |
0.2 |
2013-08-02 |
0.35 |
2013-06-26 |
0.2 |
2013-05-02 |
Split |
Date |
0.01515 : 1 |
2010-11-19 |
1.5 : 1 |
2005-09-01 |
1.1 : 1 |
2004-05-06 |
1.1 : 1 |
2003-05-01 |
1.1 : 1 |
2002-05-01 |
1.1 : 1 |
2001-11-06 |